Lobbying Filing Details

Total Spending

$947,004

Activities

7

Lobbyists

8

Gov't Entities

21

Filing Information
Filing UUID:
dee4f555-0701-43b2-9f84-e74de690987c
Type:
Q4 - 4th Quarter - Report
Period:
2016 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 19, 2017 at 9:42 PM
Income:
$0
Expenses:
$947,004
Expense Method:
Method C - Reporting amounts under section 162(e) of the Internal Revenue Code
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (7)
Activity 1
Budget/Appropriations

FDA Funding.
S.2956: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017.
H.R.5054: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017.

Lobbyists (4)
  • HEIDI WILSON
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • KATHRYN LEE ANDERSON CHADWICK
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
Activity 2
Copyright/Patent/Trademark

Inter Partes Review (IPR) process.
Patent Settlements.

Lobbyists (5)
  • HEIDI WILSON
  • MICHAEL BRZICA
  • KATHRYN LEE ANDERSON CHADWICK
  • THOMAS JAMES GARRIGAN
  • CHRISTIAN OMAR CRUZ
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
Activity 3
Health Issues

Innovation for Healthier Americans Initiative.
H.R.6: 21st Century Cures Act.

Lobbyists (7)
  • CHRISTINE SIMMON
  • HEIDI WILSON
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • KATHRYN LEE ANDERSON CHADWICK
  • THOMAS JAMES GARRIGAN
  • CHRISTIAN OMAR CRUZ
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
Activity 4
Medicare/Medicaid

Medicare Part D Program and Generic Drugs.
Medicare reimbursement for biosimilars.
Medicaid Rebate Penalty.
Medicare Part D Low Income Subsidy (LIS) Program.
CMMI Part B Drug Demo.

Lobbyists (6)
  • HEIDI WILSON
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • KATHRYN LEE ANDERSON CHADWICK
  • THOMAS JAMES GARRIGAN
  • CHRISTIAN OMAR CRUZ
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
Activity 5
Pharmacy

Implementation of Food and Drug Administration Safety and Innovation Act (FDASIA) and Generic Drug User Fee Amendments (GDUFA).
Labeling of Generic Drugs.
Biosimilars Naming.
Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products.
Prescription Drug Costs.
H.R.2841: FAST Generics Act of 2015.
H.R.1314: Bipartisan Budget Act of 2015.
Risk Evaluation and Mitigation Strategies (REMS).
Biologic Exclusivity.
Biologics Price Competition and Innovation Act (BPCIA).
Pharmaceutical exclusivity.
S.3056: CREATES Act of 2016.
H.R.6: 21st Century Cures Act.

Lobbyists (8)
  • CHRISTINE SIMMON
  • HEIDI WILSON
  • MICHAEL BRZICA
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • KATHRYN LEE ANDERSON CHADWICK
  • THOMAS JAMES GARRIGAN
  • CHRISTIAN OMAR CRUZ
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
Activity 6
Taxation/Internal Revenue Code

Taxation Issues Related to Opioid Pharmaceuticals.

Lobbyists (3)
  • HEIDI WILSON
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)
Activity 7
Trade (domestic/foreign)

Trans-Pacific Partnership (TPP).
Transatlantic Trade and Investment Partnership (TTIP).
Biologic Exclusivity.

Lobbyists (2)
  • MICHAEL BRZICA
  • KATHRYN LEE ANDERSON CHADWICK
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Office of Management & Budget (OMB)

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.